Efficacy and safety of sotatercept in pulmonary arterial hypertension: A systematic review and meta-analysis of randomized controlled trials
Indian Heart Journal · 2026-05 · 78 (3) · 144-150
DOI: 10.1016/j.ihj.2026.01.005 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Indian Heart Journal, 2026-05. Verfasst von Mohsin Raj Mantoo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, All India Institute of Medical Sciences, New Delhi, India. Hauptthemen laut MEDLINE: Randomized Controlled Trials as Topic, Recombinant Fusion Proteins, Pulmonary Arterial Hypertension. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Sotatercept, a first-in-class activin signaling inhibitor, represents a paradigm shift in pulmonary arterial hypertension (PAH) by directly targeting pulmonary vascular remodeling. We conducted a meta-analysis of randomized controlled trials (RCTs) to quantify its efficacy and safety. METHODS: We systematically searched PubMed, Embase, and Cochrane Central from inception to October 2025 for RCTs comparing sotatercept with placebo in PAH. The primary outcome was trial-defined clinical worsening (CW). Secondary outcomes included all-cause mortality, multicomponent improvement (MCI), attainment of low-risk status, serious adverse events (SAEs), and bleeding. Data were pooled using a Mantel-Haenszel random-effects model. Risk of bias was assessed with RoB 2.0, certainty of evidence using GRADE, and trial sequential analysis (TSA) was performed to assess conclusiveness. RESULTS: Four RCTs comprising 921 patients (sotatercept n = 483; placebo n = 438) were included. Sotatercept significantly reduced clinical worsening (OR 0.18, 95 % CI 0.12-0.27) with minimal heterogeneity and TSA-confirmed conclusiveness. All-cause mortality showed a favorable but non-significant trend (OR 0.63, 95 % CI 0.33-1.20). Sotatercept significantly increased MCI (OR 4.68, 95 % CI 1.94-11.31) and attainment of low-risk status (OR 2.77, 95 % CI 1.49-5.17), with moderate heterogeneity. SAEs were reduced (OR 0.72, 95 % CI 0.53-0.99), while bleeding risk was increased, predominantly minor mucocutaneous events (OR 2.84, 95 % CI 1.94-4.15). CONCLUSION: Sotatercept markedly reduces clinical worsening and improves multidimensional outcomes in PAH with an acceptable safety profile, supporting its role as a disease-modifying therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, All India Institute of Medical Sciences, New Delhi, India.
- Department of Medicine, Vardhman Mahavir Medical College and Associated Safdarjung Hospital, New Delhi, India.
- Department of Cardiology, All India Institute of Medical Sciences, New Delhi, India. Electronic address: drambujroy@gmail.com.
Zitieren
APA
Mantoo, M. R., Majeed, M. W., & Roy, A. (2026). Efficacy and safety of sotatercept in pulmonary arterial hypertension: A systematic review and meta-analysis of randomized controlled trials. Indian Heart Journal, 78(3), 144-150. https://doi.org/10.1016/j.ihj.2026.01.005
Vancouver
Mantoo MR, Majeed MW, Roy A. Efficacy and safety of sotatercept in pulmonary arterial hypertension: A systematic review and meta-analysis of randomized controlled trials. Indian Heart Journal. 2026;78(3):144-150. doi:10.1016/j.ihj.2026.01.005
BibTeX
@article{Mantoo2026,
author = {Mantoo, Mohsin Raj and Majeed, Mir Wajid and Roy, Ambuj},
title = {Efficacy and safety of sotatercept in pulmonary arterial hypertension: A systematic review and meta-analysis of randomized controlled trials},
journal = {Indian Heart Journal},
year = {2026},
volume = {78},
number = {3},
pages = {144--150},
doi = {10.1016/j.ihj.2026.01.005}
}
EUVIMED